title: Adenosine and inosine exert cytoprotective effects in an in vitro model             of liver ischemia-reperfusion injury.
abstract: Liver ischemia represents a common clinical problem. In the present study, using an in vitro model of hepatic ischemia-reperfusion injury, we evaluated the potential cytoprotective effect of the purine metabolites, such as adenosine and inosine, and studied the mode of their pharmacological actions. The human hepatocellular carcinoma-derived cell line HepG2 was subjected to combined oxygen-glucose deprivation (COGD; 0-14-24 h), followed by re-oxygenation (0-4-24 h). Adenosine or inosine (300-1,000 µM) were applied in pretreatment. Cell viability and cytotoxicity were measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and lactate dehydrogenase methods, respectively. The results showed that both adenosine and inosine exerted cytoprotective effects, and these effects were not related to receptor-mediated actions, since they were not prevented by selective adenosine receptor antagonists. On the other hand, the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, 10 µM) markedly and almost fully reversed the protective effect of adenosine during COGD, while it did not influence the cytoprotective effect of inosine in the same assay conditions. These results suggest that the cytoprotective effects are related to intracellular actions, and, in the case of adenosine also involve intracellular conversion to inosine. The likely interpretation of these findings is that inosine serves as an alternative source of energy to produce ATP during hypoxic conditions. The protective effects are also partially dependent on adenosine kinase, as the inhibitor 4-amino-5-(3-bromophenyl)-7-(6‑morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, 2HCl (ABT 702, 30 µM) significantly reversed the protective effect of both adenosine and inosine during hypoxia and re-oxygenation. Collectively, the current results support the view that during hypoxia, adenosine and inosine exert cytoprotective effects via receptor-independent, intracellular modes of action, which, in part, depend on the restoration of cellular bioenergetics. The present study supports the view that testing of inosine for protection against various forms of warm and cold liver ischemia is relevant.
authors.affiliation: Department of Anesthesiology, University of Texas Medical Branch,                     Galveston, TX 77555, USA.
authors.forename: Katalin
authors.initials: K
authors.lastname: Módis
authors.forename: Domokos
authors.initials: D
authors.lastname: Gerő
authors.forename: Rita
authors.initials: R
authors.lastname: Stangl
authors.forename: Olivér
authors.initials: O
authors.lastname: Rosero
authors.forename: Attila
authors.initials: A
authors.lastname: Szijártó
authors.forename: Gábor
authors.initials: G
authors.lastname: Lotz
authors.forename: Petra
authors.initials: P
authors.lastname: Mohácsik
authors.forename: Petra
authors.initials: P
authors.lastname: Szoleczky
authors.forename: Ciro
authors.initials: C
authors.lastname: Coletta
authors.forename: Csaba
authors.initials: C
authors.lastname: Szabó
mesh_terms: D000241:Adenosine / Q000494:pharmacology / Q000627:therapeutic use*; D019610:Cytoprotection / Q000187:drug effects*; D056945:Hep G2 Cells; D006801:Humans; D007288:Inosine / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology
chemical_list: D007288:Inosine; D000241:Adenosine